Pelthos Therapeutics Inc（PTHS）股票分析

AI 分析 of Pelthos Therapeutics Inc (PTHS)

持有

Pelthos Therapeutics Inc is not a strong buy at the moment due to its current price of $11.52, which is significantly below its 52-week high of $37.50. The RSI is at 31.083, indicating that the stock is oversold, but the recent performance shows a 5-day change of -24.21% and a year-to-date change of -60.88%. While there are positive catalysts such as revenue growth to $10.7 million in Q1 2026 and a strategic merger with Castle Creek, the company still faces significant financial challenges, including a net loss of $10.2 million in Q1 and a forward P/E ratio of 0, suggesting uncertainty in profitability. The main risk is the high volatility in prescription trends for its lead product ZELSUVMI, which analysts have noted as flat. Therefore, while there may be potential for recovery, the current financial instability and market conditions suggest a cautious approach.

估值指標

Pelthos Therapeutics Inc（PTHS）目前預期本益比為 0.00，5 年平均預期本益比為 -7.52。

預期本益比

高估

5 年均值 P/E

-7.52

目前P/E

0.00

高估

-2.80

低估

-12.25

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-1.03

目前EV/EBITDA

-0.81

高估

0.01

低估

-2.07

預期股價營收比

合理

5 年均值 P/S

1.33

目前P/S

0.34

高估

2.65

低估

0.01

Alphio AI 對 PTHS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%PTHS

$26.27

情境價格

基

基準

基準 · 50%PTHS

$23.56

情境價格

悲

悲觀

悲觀 · 25%PTHS

$23.29

情境價格

PTHS 常見問題 —— 由 Alphio AI 解答

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older. It operates in the Healthcare sector.

Pelthos Therapeutics Inc is not a strong buy at the moment due to its current price of $11.52, which is significantly below its 52-week high of $37.50. The RSI is at 31.083, indicating that the stock is oversold, but the recent performance shows a 5-day change of -24.21% and a year-to-date change of -60.88%. While there are positive catalysts such as revenue growth to $10.7 million in Q1 2026 and a strategic merger with Castle Creek, the company still faces significant financial challenges, including a net loss of $10.2 million in Q1 and a forward P/E ratio of 0, suggesting uncertainty in profitability. The main risk is the high volatility in prescription trends for its lead product ZELSUVMI, which analysts have noted as flat. Therefore, while there may be potential for recovery, the current financial instability and market conditions suggest a cautious approach.